20-Mar-2025 8:45 AM CST - The Motley Fool 3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025 If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The pharmaceutical giant isn't as risky an investment as it may appear to be. Its financials aren't in bad shape,
19-Mar-2025 12:28 PM CST - Yahoo Finance Pfizer (NYSE:PFE) To Divest Entire 7 Percent Stake In Haleon Through Share Offering Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment strategy that prominently featured an accelerated book building process aimed at institutional investors.
18-Mar-2025 1:26 PM CST - Yahoo Finance Pfizer Set to Raise $3.3 Billion in Final Haleon Stake Sale Pfizer Inc. is looking to sell its remaining 7.3% stake in Haleon Plc, culminating a multi-year separation from the maker of Sensodyne toothpaste.Most Read from BloombergICE Eyes Massive California Tent Facility Amid Space ConstraintsHow Britain's Most Bike-Friendly New Town Got BuiltThe Dark Prophet of Car-Clogged CitiesWashington,
18-Mar-2025 12:25 PM CST - Morningstar Pfizer to Dispose of Remaining Shareholding in Haleon Haleon--which owns brands such as Sensodyne toothpaste, Aquafresh mouthwash and over-the-counter medicines Panadol and Advil--was formed in July 2019 through the merger of GSK and Pfizer's consumer-healthcare businesses. It was subsequently spun off and listed on the London Stock Exchange in July 2022.
18-Mar-2025 9:00 AM CST - Business Wire Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizers results, as reflected in the companys First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Inf
14-Mar-2025 12:35 PM CST - Yahoo Finance Pfizer (NYSE:PFE) Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious discrimination and executive pay structures, with the company advising shareholders to vote against these proposals at the forthcoming annual meeting.
11-Mar-2025 12:39 PM CST - Yahoo Finance Pfizer (NYSE:PFE) Announces Promising Phase 3 Results For Breast Cancer Therapy Vepdegestrant Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in treating advanced breast cancer, which could be a significant driver of the company's modest 4% price increase over the last quarter.
10-Mar-2025 7:52 AM CST - Yahoo Finance Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold? Pfizer's PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple of years due to declining sales of its COVID products with the end of the pandemic.
Latest PFE Trades by Congress Members
26-FEB-2025 - Gilbert Cisneros, CA (District 31) purchased between $1,001 and $15,000.
20-Mar-2025 8:45 AM CST - The Motley Fool 3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025 If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The pharmaceutical giant isn't as risky an investment as it may appear to be. Its financials aren't in bad shape,
19-Mar-2025 12:28 PM CST - Yahoo Finance Pfizer (NYSE:PFE) To Divest Entire 7 Percent Stake In Haleon Through Share Offering Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment strategy that prominently featured an accelerated book building process aimed at institutional investors.
18-Mar-2025 1:26 PM CST - Yahoo Finance Pfizer Set to Raise $3.3 Billion in Final Haleon Stake Sale Pfizer Inc. is looking to sell its remaining 7.3% stake in Haleon Plc, culminating a multi-year separation from the maker of Sensodyne toothpaste.Most Read from BloombergICE Eyes Massive California Tent Facility Amid Space ConstraintsHow Britain's Most Bike-Friendly New Town Got BuiltThe Dark Prophet of Car-Clogged CitiesWashington,
18-Mar-2025 12:25 PM CST - Morningstar Pfizer to Dispose of Remaining Shareholding in Haleon Haleon--which owns brands such as Sensodyne toothpaste, Aquafresh mouthwash and over-the-counter medicines Panadol and Advil--was formed in July 2019 through the merger of GSK and Pfizer's consumer-healthcare businesses. It was subsequently spun off and listed on the London Stock Exchange in July 2022.
18-Mar-2025 9:00 AM CST - Business Wire Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizers results, as reflected in the companys First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Inf
14-Mar-2025 12:35 PM CST - Yahoo Finance Pfizer (NYSE:PFE) Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious discrimination and executive pay structures, with the company advising shareholders to vote against these proposals at the forthcoming annual meeting.
11-Mar-2025 12:39 PM CST - Yahoo Finance Pfizer (NYSE:PFE) Announces Promising Phase 3 Results For Breast Cancer Therapy Vepdegestrant Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in treating advanced breast cancer, which could be a significant driver of the company's modest 4% price increase over the last quarter.
10-Mar-2025 7:52 AM CST - Yahoo Finance Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold? Pfizer's PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple of years due to declining sales of its COVID products with the end of the pandemic.
